Home / Health / GLP-1 Drugs: MHRA Warns of Severe Pancreatitis Risk
GLP-1 Drugs: MHRA Warns of Severe Pancreatitis Risk
9 May
Summary
- MHRA alerts patients and doctors to rare but serious GLP-1 side effect.
- Severe pancreatitis symptoms include persistent, intense stomach pain.
- GLP-1 drugs are widely used for diabetes and weight management.
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) is emphasizing the need for vigilance regarding a rare, severe side effect of GLP-1 medications. Patients and healthcare providers are urged to recognize the warning signs of acute pancreatitis, a condition involving sudden inflammation of the pancreas.
Symptoms to watch for include severe, persistent abdominal pain that may extend to the back, often accompanied by nausea and vomiting. While most cases of acute pancreatitis resolve within a week, severe instances can lead to more serious health consequences. The MHRA has updated product information to ensure users are aware of this risk.
These GLP-1 drugs, including Ozempic, Wegovy, and Mounjaro, are prescribed for type 2 diabetes, weight management, and cardiovascular risk reduction. Recent research suggests millions of adults in England, Wales, and Scotland have used them for weight loss. Although generally safe and effective, the MHRA stresses that awareness of pancreatitis symptoms and seeking immediate medical help are vital.
